KRAS and neuroendocrine carcinoma: While both PDAC and NEC can exhibit TP53 mutations, PDAC is primarily defined by KRAS, CDKN2A, and SMAD4 mutations, whereas NEC is characterized by ATRX, DAXX, and MEN1 mutations [[22], [23], [24]].